RELMADA THERAPEUTICS INC (RLMD)
US75955J4022 - Common Stock
RELMADA THERAPEUTICS INC
NASDAQ:RLMD (1/3/2025, 8:00:02 PM)
After market: 0.46 -0.01 (-2.15%)0.4701
+0.02 (+4.44%)
Company Profile
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on addressing diseases of the central nervous system. The company is headquartered in Coral Gables, Florida and currently employs 20 full-time employees. The company went IPO on 2014-03-03. The firm is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.
Company Info
RELMADA THERAPEUTICS INC
2222 Ponce De Leon Blvd. 3Rd Floor
Coral Gables FLORIDA 10022
P: 16468763459
CEO: Sergio Traversa
Employees: 20
Website: https://www.relmada.com/
RLMD News
26 days ago - Relmada TherapeuticsRelmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder Value...
a month ago - Relmada TherapeuticsRelmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical SignificanceThe DMC did not identify any new safety concerns Relmada to evaluate potential next steps for the REL-1017 program Relmada to continue to focus on the...
2 months ago - Relmada TherapeuticsRelmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic DiseaseREL-P11 is a proprietary, low-dose, modified-release psilocybin formulation Single-Ascending Dosing (SAD) study to evaluate safety and pharmacokinetics in...
2 months ago - Relmada Therapeutics, Inc.Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update/PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada", "the Company"), a late-stage biotechnology company addressing diseases of the central...
2 months ago - Relmada TherapeuticsRelmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdatePre-planned Phase 3 Reliance II interim analysis, anticipated by YE 2024, could represent an important de-risking event for REL-1017 and the Company ...
2 months ago - Relmada TherapeuticsRelmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024CORAL GABLES, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology company addressing...
RLMD Twits
Here you can normally see the latest stock twits on RLMD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
